LEGNLegend Biotech Corporation
$18.62-45% 1Y
$18.62
$16.6552 weeks$36.28
LEGN as reported
Legend Biotech Corporation reported $909M of revenue over the trailing twelve months. 10 reported series are charted on this page, each one as filed.
$909M
Revenue, trailing twelve months · to Q3 2025 · every figure below is as filed, with no scoring applied
- Net income
- −$297M
Net income · +68% year on year · trailing twelve months to Q4 2025
- Free cash flow
- −$129M
Free cash flow · −19% year on year · trailing twelve months to Q4 2025
- EPS
- −$0.81
EPS · +72% year on year · trailing twelve months to Q4 2025
Details›
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $909M | n/a | Q3 2025 |
| Net income | −$297M | +68% | Q4 2025 |
| EPS | −$0.81 | +72% | Q4 2025 |
| Gross margin | 62% | n/a | Q3 2025 |
| Operating margin | 9.2% | n/a | Q4 2024 · 4 quarters behind |
| Net margin | −25% | n/a | Q3 2025 |
| ROE | −27% | n/a | Q4 2025 |
| ROA | −16% | n/a | Q4 2025 |
| ROIC | 14% | n/a | Q4 2024 · 4 quarters behind |
| Free cash flow | −$129M | −19% | Q4 2025 |
Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.
Legend Biotech Corporation (LEGN) · Revenue and profitRevenue and profitLegend Biotech Corporation (LEGN)
RevenueNet incomeTrailing twelve months
Powered byryufin.com
On our screens:Stocks with no debt